Survival Outcome and EMT Suppression Mediated by a Lectin Domain Interaction of Endo180 and CD147

• Published in: Molecular cancer research Vol. 13; no. 3; pp. 538 - 547
• Main Authors: Rodriguez-Teja, Mercedes, Gronau, Julian H, Minamidate, Ai, Darby, Steven, Gaughan, Luke, Robson, Craig, Mauri, Francesco, Waxman, Jonathan, Sturge, Justin
• Format: Journal Article
• Language: English
• Published: United States 01.03.2015
• Subjects: Basigin - metabolism; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Humans; Male; Mannose-Binding Lectins - chemistry; Mannose-Binding Lectins - metabolism; Membrane Glycoproteins - chemistry; Membrane Glycoproteins - metabolism; Prognosis; Prostatic Neoplasms - chemistry; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Proteomics; Receptors, Cell Surface - chemistry; Receptors, Cell Surface - metabolism; Survival Analysis
• ISSN: 1541-7786; 1557-3125
• DOI: 10.1158/1541-7786.MCR-14-0344-T

Epithelial cell-cell contacts maintain normal glandular tissue homeostasis, and their breakage can trigger epithelial-to-mesenchymal transition (EMT), a fundamental step in the development of metastatic cancer. Despite the ability of C-type lectin domains (CTLD) to modulate cell-cell adhesion, it is not known if they modulate epithelial adhesion in EMT and tumor progression. Here, the multi-CTLD mannose receptor, Endo180 (MRC2/uPARAP), was shown using the Kaplan-Meier analysis to be predictive of survival outcome in men with early prostate cancer. A proteomic screen of novel interaction partners with the fourth CTLD (CTLD4) in Endo180 revealed that its complex with CD147 is indispensable for the stability of three-dimensional acini formed by nontransformed prostate epithelial cells (PEC). Mechanistic study using knockdown of Endo180 or CD147, and treatment with an Endo180 mAb targeting CTLD4 (clone 39.10), or a dominant-negative GST-CTLD4 chimeric protein, induced scattering of PECs associated with internalization of Endo180 into endosomes, loss of E-cadherin (CDH1/ECAD), and unzipping of cell-cell junctions. These findings are the first to demonstrate that a CTLD acts as a suppressor and regulatory switch for EMT; thus, positing that stabilization of Endo180-CD147 complex is a viable therapeutic strategy to improve rates of prostate cancer survival. This study identifies the interaction between CTLD4 in Endo180 and CD147 as an EMT suppressor and indicates that stabilization of this molecular complex improves prostate cancer survival rates.